Poster # 2385 Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases

Presenter: Sten Nilsson, MD, PhD


Abstract:


E-mail a friend about this poster:
Enter email address: